Clinical trials: IgAN - IgA Nephropathy
Primary IgA Nephropathy
Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy
NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.
- Trial name
- NCT06982040
- Testing
- NTQ5082 capsules 100 mg, NTQ5082 capsules 200 mg, NTQ5082 capsules 300 mg
- Volunteers
- 80 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
IgA Nephropathy
SodiUm Restriction by Behavioral Intervention
The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy.
- Trial name
- SURBI (NCT04805047)
- Testing
- education and monitoring
- Where
- China
- Volunteers
- 142 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
IgA Nephropathy (IgAN)
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of…
- Trial name
- LUMINA IgAN (NCT07850752)
- Testing
- zigakibart, atrasentan
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals
Glomerulonephritis, IGA, Renal Insufficiency, Chronic
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
IgA nephropathy is the most common primary glomerulonephritis in the world. Because of the poor treatment effect in advanced patients, it is still the main cause of maintenance dialysis.
- Trial name
- NCT04020328
- Testing
- Leflunomide 20 mg+prednisone 0.5mg/kg/d
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shenzhen Second People's Hospital
IgA Nephropathy (IgAN), Renal and Urinary Disorders
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Trial name
- ORIGIN EXTEND (NCT06674577)
- Testing
- Atacicept 150 mg
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Vera Therapeutics, Inc.
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Nephropathy
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
- Trial name
- NCT07642050
- Testing
- BHV-1400
- Volunteers
- 420 people
- Sponsor
- Biohaven Therapeutics Ltd.
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
IgA Nephropathy
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
IgA nephropathy (IgAN) is one of the most common glomerular diseases worldwide. Current treatments for IgAN are limited by their relatively insufficient efficacy and severe adverse events.
- Trial name
- NCT03633864
- Testing
- Fecal microbiota transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Air Force Military Medical University, China
Glomerulonephritis, IgAN
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by immunofluorescence.
- Trial name
- PIRAT (NCT02523768)
- Testing
- ATG-F, Simulect
- Where
- 15 sites in France
- Volunteers
- 117 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IgA Nephropathy
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16…
- Trial name
- NefXtend (NCT06712407)
- Testing
- TARPEYO®
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Calliditas Therapeutics AB
IgA Nephropathy
Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy
The purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(SCr) in IgA Nephropathy
- Trial name
- IgAN (NCT00549692)
- Testing
- Omega-3 fatty acid ethylester90
- Where
- 5 sites in South Korea
- Volunteers
- 152 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Immunoglobulin A Nephropathy (IgAN)
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
- Trial name
- SHIFT (NCT07146906)
- Testing
- zigakibart
- Where
- 30 sites in United States, Brazil and 9 more
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Glomerulonephritis, IGA, Glomerulonephritis, Membranous
Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Morning urine samples of patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from November 2020 to January…
- Conditions
- Glomerulonephritis, IGA, Glomerulonephritis, Membranous, Diabetic Nephropathies, Nephrosis, Lipoid
- Trial name
- NCT05797051
- Testing
- Microscopic hyperspectral imaging system
- Volunteers
- 80 people
- Sponsor
- Qianfoshan Hospital
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Primary IgA Nephropathy
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
- Trial name
- NCT04291781
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RemeGen Co., Ltd.
IGA Nephropathy
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
- Trial name
- NCT02112838
- Testing
- Fostamatinib 150 mg, Fostamatinib 100 mg
- Where
- 20 sites in United States, Austria and 4 more
- Volunteers
- 76 people
- Sponsor
- Rigel Pharmaceuticals
Chronic Kidney Disease, IgA Nephropathy
Pilot Study of Velcade® in IgA Nephropathy
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy.
- Trial name
- NCT01103778
- Testing
- Bortezomib (Velcade®)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Rogosin Institute
IgA Nephropathy
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
A multi-center, randomized, controlled clinical trial to evaluate the short-term and long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function in patients with IgAN who…
- Trial name
- NCT00657059
- Testing
- irbesartan, methylprednisolone (MP) or prednisone (pred), mycophenolate mofetil (MMF)
- Where
- China
- Volunteers
- 151 people
- Sponsor
- Sun Yat-sen University
Finerenone, IgA Nephropathy
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited…
- Conditions
- Finerenone, IgA Nephropathy, Proteinuria, Safety Issues
- Trial name
- NCT06460987
- Testing
- Finerenone, RAS inhibitor, Immune Suppressant
- Where
- China
- Volunteers
- 245 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine